DXCM Grew. The Stock Did Not. Someone Is Wrong

The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.

Over the past year, DexCom (DXCM), a leader in the Health Care Equipment industry and a maker of continuous glucose monitoring systems for people with diabetes, grew its revenue by 16.1%. Its stock, meanwhile, delivered a return of -12.8%. This is the kind of disconnect that stops you cold: the business performed, but the market shrugged, quietly erasing a portion of the company’s valuation multiple along the way. The divergence suggests investors are weighing a management team delivering double-digit growth against a market that has already priced in a slowdown.

What does a 27% multiple compression actually price in?

The market’s verdict is written in the price-to-sales multiple, which compressed 27% over the last twelve months. This isn’t a reaction to sudden unprofitability; on the contrary, the company’s operating margin is up year over year. Instead, the market is signaling a deep skepticism about the durability of DexCom’s growth. A lower multiple means investors are willing to pay less for each dollar of future sales, implying a belief that the current 16.1% growth rate is unsustainable.

This skepticism runs counter to the company’s own forecast. Management is “reaffirming our prior revenue guidance of $5.16 billion to $5.20 billion,” which represents growth of 11% to 13% for the year. While a step down from the trailing rate, it’s a far cry from the sharp deceleration the stock’s valuation implies, pitting management’s confidence against the market’s doubt.

Is the market seeing a U.S. slowdown that management cannot admit?

The market’s pessimism appears rooted in a potential crack in the business story: the U.S. market. On the company’s latest earnings call, analysts noted that the U.S. continuous glucose monitoring market “is in a period of slower growth.” One pointed out that DexCom is now a “full year without a record new patient start” in the United States, a critical engine for its expansion.

This suggests the company may be approaching saturation among its core, currently-covered patient groups. Future growth, then, becomes heavily dependent on a single, large catalyst: securing Medicare coverage for the large population of people with Type 2 diabetes who do not use insulin. Management insists this decision is “only a matter of time,” but the market is notoriously impatient with growth stories that hinge on an event with no firm date. The stock is priced as if this catalyst is either very far off or will be less impactful than hoped, creating a potential growth gap.

Will the new Type 2 trial data force a verdict?

Management’s answer to the slowdown narrative rests on execution. The company is already seeing “strong share gains” among people with Type 2 diabetes not on insulin, aided by new commercial coverage wins like one from Prime Therapeutics. But the most powerful piece of evidence it can offer is clinical data. DexCom recently presented a “full readout” of its randomized control trial for this exact patient group at the ADA’s 2026 Scientific Sessions.

The results from this study, called CONNECT, showed a “clinically and statistically significant reduction in A1C.” This is precisely the kind of data designed to convince large payers like CMS to expand coverage. The market’s reaction to this evidence will ultimately resolve the tension between the company’s performance and its stock price. All eyes are now on the timeline for a Medicare coverage decision.

For more stocks the market has marked down while the business held up, our Buy the Dip screen does exactly that screen, daily.

Prefer the theme to this single name? A Nasdaq ETF like QQEW owns the whole group. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.

When The Market Goes Quiet, Diversification Does The Talking

A stock the market quietly repriced can stay cheap far longer than any thesis survives. Watching one name and waiting for recognition is a strategy that tests patience more than judgment.

The Trefis High Quality (HQ) Portfolio spreads that wait across about 30 quality businesses chosen on cash flow, margins, and balance-sheet strength, sized and rebalanced with discipline, so no single overlooked story has to be discovered for the portfolio to work. It has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Keep an eye on the quiet reprices; let a diversified core carry the meantime.